Sangamo Therapeutics (FRA:GBY) Research & Development: €97.29 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Sangamo Therapeutics Research & Development?

Sangamo Therapeutics FRA:GBY Research & Development is €97.29 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Sangamo Therapeutics's Research & Development for the three months ended in Mar. 2026 was €22.98 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €97.29 Mil.

Sangamo Therapeutics  (FRA:GBY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sangamo Therapeutics Research & Development Related Terms

Sangamo Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Sangamo Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sangamo Therapeutics Research & Development Chart

Sangamo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 204.28 235.90 214.63 106.50 96.22

Sangamo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.06 23.48 23.98 26.85 22.98

Sangamo Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €97.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €97.29 Mil mean?
Sangamo Therapeutics (FRA:GBY) has a Research & Development of €97.29 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Sangamo Therapeutics and its competitors.
Is Sangamo Therapeutics' Research & Development too high?
Sangamo Therapeutics' current Research & Development is €97.29 Mil.
How does Sangamo Therapeutics' Research & Development compare to LSTA and LITS?
Sangamo Therapeutics' Research & Development of €97.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Sangamo Therapeutics and its competitors. Sangamo Therapeutics's current Research & Development is €97.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sangamo Therapeutics stock overvalued right now?
Sangamo Therapeutics (FRA:GBY) has a current Research & Development of €97.29 Mil. The stock's GF Value™ is €0.18, compared to a current price of €0.07 — trading 63.2% below its estimated fair value. The current Research & Development is €97.29 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Sangamo Therapeutics (FRA:GBY), the current Research & Development is €97.29 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sangamo Therapeutics Business Description

Other Exchanges SGMO:USA0R1D:UKGBY:Germany
Address 501 Canal Boulevard, Richmond, CA, USA, 94804
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.